National Cancer Center, Japan

• Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

  Phase 2, Recruiting, 29 people, 14 Oct 2026

• NCT07699939

  Phase 2, Recruiting, 136 people, 13 Jul 2026

• NCT05832827

  Phase 2, Recruiting, 35 people, 27 Apr 2023

• NCT03423199

  Phase 3, Status unknown, 180 people, 6 Feb 2018

Sources: clinicaltrials.gov

• Japanese Diet Index Score and Cause-Specific Mortality in Japanese Men and Women: The Japan Public Health Center-Based Prospective Study

  10 Sept 2025

Sources: api.crossref.org